KR101507973B1 - Crystalline Bepotastine and it's process for the preparation - Google Patents

Abstract

The present invention relates to crystalline (S) -4- [4 - [(4-chlorophenyl) - (2-pyridyl) methoxy] piperidin- 1-yl] butanoic acid of the formula (I) (2-pyridyl) methoxy] piperidin-1-yl] butanoic acid compound is reacted with 1, ) Water, 2) alcoholic solvents such as methanol, ethanol, furovanol, butanol, isoamyl alcohol and ethylene glycol, 3) aromatic hydrocarbon solvents such as benzene, toluene and xylene, 4) acetic acid ethers such as methyl acetate and ethyl acetate Solvent, 5) ketone solvents such as acetonitrile, acetone, methyl ethyl ketone and methyl isobutyl ketone, 6) ethyl ether, isopropyl phthalate, (7) an ether solvent such as tetrahydrofuran, tetrahydrofuran, and 2- (2-methoxyethoxy) ethane; 7) one or more horns To a process for preparing high-purity, stable crystalline bead potentin (I) and a compound thereof by adding beportantine in a solvent at a weight ratio of 10-30% by weight and refluxing at room temperature to reflux temperature for 2-72 hours .

Description

[0001] Crystalline Bepotastine and it's process for the preparation [

The present invention relates to a benzenesulfonic acid salt of (S) -4- [4- (4-chlorophenyl) -2-pyridyl] methoxy] piperidinobutanoic acid (I) having excellent antihistamine activity and antiallergic activity or Amorphous non-amorphous beatifastine of (S) -4- [4- (4-chlorophenyl) -2-pyridyl] methoxy] piperidinobutanoic acid (I) And a manufacturing method thereof.

The present invention relates to a process for preparing a compound of formula (I) by preparing a compound of formula (I) by a known preparation method and then adding it to a reaction mixture comprising 1) water, 2) an alcoholic solvent such as methanol, ethanol, furopanol, butanol, isoamyl alcohol, 4) ketone solvents such as acetonitrile, acetone, methyl ethyl ketone, and methyl isobutyl ketone; 6) ketone solvents such as ethyl ether, isopropyl alcohol, Ether solvents such as ether, dioxane, tetrahydrofuran, diglyme, diphenyl ether and 1-methoxy-2- (2-methoxyethoxy) ethane, 7) dimethyfformamide and dimethylsulfoxide groups Isobutastine is added in a weight ratio of 10-30% based on the solvent, and the mixture is refluxed at room temperature to reflux temperature for 2-72 hours, cooled at room temperature and filtered to obtain crystalline beatifastine Manufactured .

The bepotastine represented by the above formula (I) can be obtained by a method wherein the chemical name is (S) -4- [4- [(4-chlorophenyl) -2-pyridyl] methoxy] piperidinobutanoic acid, The acid-labile beptatastine bezylate or bepotastine benzoate salt compound obtained by reacting a compound with benzenesulfonic acid or benzoic acid exhibits potent antihistaminic and antiallergic activity.

Japanese Patent Laid-Open Publication No. 25465/1991 discloses BePotastine as a racemic compound for the first time, and Japanese Patent Laid-Open Publication 2000-198784 discloses a method in which a racemic compound (V) is reacted with an optically active propionic acid compound (VI) or an optically active N-acyl-amino acid, and the resulting two diastereomeric salts (VIII) is added to (S) -4 - [(4-chlorophenyl) -2-pyridylmethoxy] piperidine (VII) obtained by isolating the stereoisomer salt separately from the salt, (IX) is obtained by reacting a compound of the formula (I) with a halogen acid ester, followed by hydrolysis thereof to prepare amber amorphous bepotastine (I) compound.

Wherein R represents a lower alkyl group such as hydrogen, a methyl group or an ethyl group,

X is a halogen atom, Y is a hydrogen atom or a halogen atom, and Z is a lower alkoxy group.

However, since beptaustin obtained by the conventional method as described above is obtained in an amber amorphous syrup state, it is highly hygroscopic in the atmosphere and absorbs moisture and absorbs moisture in a short time, so that it is converted into a deliquescent substance. Has not been able to formulate the finished product until now.

Thus, the original developer of the Ube alpine of Japan made of salted acid to sulfonic acid to benzoic acid in the chopping Porta sustaining been prepared the final product, that in a trade name other Leone ^® having the highest reliability is a chopping Porta sustaining benzenesulfonate far It has been evaluated as the most stable compound among commercialized bepotastine preparations.

However, this product also has a disadvantage in terms of stability, manufacturing process and cost competitiveness,

First, it is unstable due to strong hygroscopicity in terms of stability,

Second, from the viewpoint of the manufacturing process, the final product is prepared by adding an organic acid sulfonic acid, an organic sulfonic acid, called benzenesulfonic acid, for the final product, which is disadvantageous in not only the process hassle but also the manufacturing cost.

Therefore, the present inventors have found that the present inventors have succeeded in improving various conventional disadvantages as described above, that is, they have obtained a crystalline type beptatastine which is improved in the hygroscopicity by about 40 to 90 times as much as the amorphous form and has almost no hygroscopicity, And the comparative advantage of the unit price.

The present invention facilitates the purification process by converting the amorphous syrupped bepotastine produced in the reaction process to crystalline beatifastine, resulting in the production of beportastine with high purity and excellent stability, And to provide a stable material.

The present invention relates to a process for the preparation of amorphous (S) - (+) - 4- [4- [4-chlorophenyl) - (2- pyridyl) methoxy] piperidino] And a method for converting a carbonic acid compound into a stable and highly pure crystalline beatifastine which has no hygroscopicity readily after it is obtained.

Accordingly, the present invention relates to a crystalline form of non-hygroscopic beetapastin which is excellent in stability under pharmaceutical conditions, a process for producing the same, and an antihistamine or a pharmaceutical composition for an allergy comprising the same as an effective ingredient.

First, the present invention relates to a process for preparing a crystalline form of (S) -4- [4- [4-chlorophenyl) - (2-pyridyl) methoxy] piperidin- to provide.

The objective compound of the present invention represented by the above formula (I) will be described in detail.

1) dissolving amorphous bepotastine in an appropriate solvent;

2) dissolving amorphous bepotastine, warming, and refluxing at room temperature to the boiling point of the solvent used;

3) stirring the mixture to obtain a solid, which is filtered, washed and dried at room temperature to form crystalline beatifastine.

The process for the preparation of crystalline beatifastine according to the present invention describes in more detail below some important factors for converting amorphous beportatine into crystalline form in a solution containing bevetastine.

1) When amorphous bepotastine is dissolved in a solvent, it is important to control the concentration of beportatin in the reaction solution. In order to promote the crystallization efficiently, the concentration of beportastine is adjusted to 10-30% .

2) The reaction temperature of the amorphous beptalatine-containing reaction liquid is refluxed for 2 to 72 hours, preferably 12 to 24 hours, at room temperature to reflux temperature to convert to a crystalline form.

3) In the step of aging the crystalline beatifastine, the temperature is cooled from the reflux temperature to room temperature, and the time necessary for cooling is aged for 2-6 hours, preferably 2-4 hours, and crystals are formed and filtered.

Amorphous bepotastine can be produced by a method comprising the steps of: 1) water; 2) an alcohol solvent such as methanol, ethanol, furopanol, butanol, isoamyl alcohol or ethylene glycol; 3) aromatic solvents such as benzene, toluene, Hydrocarbon solvents, 4) acetic acid ether solvents such as methyl acetate and ethyl acetate, 5) ketone solvents such as acetonitrile, acetone, methyl ethyl ketone and methyl isobutyl ketone, 6) ethyl ether, isofluoryl ether, dioxane, tetra Ether solvents such as tetrahydrofuran, diglyme, diphenyl ether and 1-methoxy-2- (2-methoxyethoxy) ethane; 7) dimethylformamide and dimethyl sulfoxide; In the above mixed solvents, beportantine is added in a weight ratio of 10-30% by weight, preferably 15-20% by weight based on the solvent, at room temperature to reflux temperature, preferably at 30 占 폚 to reflux temperature, more preferably at 50 占 폚, After heating to dissolve, the crystals are precipitated by refluxing for 2-72 hours, preferably 6-48 hours, more preferably 12-24 hours, cooling to room temperature and filtration to obtain crystalline beatifastine.

If the solvent ratio is less than 10% or more than 30% by weight of amorphous bevapatastine, the target compound is obtained at a very low yield even if the desired crystalline beatifastine is not obtained or is obtained.

Also, when the crystal transformation time was less than 2 hours, complete conversion of crystals could not be expected. If the crystal transformation time was more than 72 hours, a complicated polymer material was formed and the desired free salt of beportantine could not be obtained.

The crystalline form of the crystalline beatifastine obtained according to the present invention is characterized by a characteristic 2 theta (2 theta) diffraction angular peak, a relative peak intensity according to each diffraction angle, and a distance between the crystal faces appearing in an XRD spectrum irradiated with _a CuK _a light source .

Specifically, the one embodiment crystalline chopping Porta sustaining is more than 30% relative intensity in the XRD according to the invention: The peak having the (Ⅰ / I ₀ Ⅰ the intensity of each peak I ₀ is the intensity of the largest peak) (2θ ± 0.2) at the diffraction angles (10.theta., 10.60, 15.60, 15.88, 16.32, 16.76, 17.39, 18.09, 19.54, 19.89, 20.74, 22.28, 23.39, 24.73, 25.25, 27.39, 29.07, 29.94, 30.63, 32.43 and 33.06 Crystal structure (see Fig. 1 and Table 1).

The crystalline bevetastatin of the formula [I] thus obtained exhibits a high optical purity of 99.9% or more and an HPLC purity of 99.99% or more, and is also in a non-hygroscopic crystal form and has excellent optical stability compared to the conventional bevetastinsulfonate , The pharmaceutical composition containing the same can maintain high optical purity and stability even under various conditions such as high temperature and high humidity, and therefore, it is advantageous for preparation, distribution and storage, and can maintain high purity for a long period of time. Furthermore, the thus obtained crystalline beatifastine can be formulated into pharmaceutically acceptable formulations such as tablets, capsules and powders together with one or more excipients.

The present invention is advantageous in that the reaction process is very simple, and crystalline beapotastin (I) having high optical stability and high hygroscopicity and high hygroscopicity can be obtained.

1 is an XRD spectrum of crystalline beatifastine according to Example 1. Fig.
2 is an IR spectrum of crystalline beatifastine according to Example 1. Fig.
3 is an XRD spectrum of amorphous bepotastine according to Example 18. Fig.
4 is an IR spectrum of amorphous bepotastine according to Example 18. Fig.
The present invention will be described in more detail with reference to the following examples, but the present invention is not limited thereto.

Example  1. (S) -Crystal Bepotastine  Produce

(S) -bipotastine (5.0 g) is dissolved in 25 ml of ethyl acetate to prepare a homogeneous solution. After stirring at room temperature for 3 hours, the solvent was removed from the solution under reduced pressure, and 30 ml of ethyl acetate was further added to the residue, followed by stirring at room temperature for 3 days.

The solvent was removed by further decompression, 30 ml of acetonitrile was added to the residue, and the mixture was stirred at room temperature for 3 hours to obtain the desired compound (4.9 g) as a crystalline form.

Melting point: 160-163 ° C

¹ H NMR (CDCl ₃ ):? 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 (4H), 3.5 (1H), 5.45 (1H), 7.0-7.2 (4H), 7.6-7.8 (1H), 8.5 (1H)

IR (KBr): 3348 cm-, 2931 cm-, 2345 cm-, 1728 cm-, 1590 cm-, 1172 cm-, 1080 cm-.

HPLC (purity): 99.99% or more

HPLC (optical purity): 99.9% or more

The XRD spectrum of the crystalline beatifastine according to Example 1 of the present invention is shown in FIG. 1, and the IR spectrum is shown in FIG. 2. The diffraction angle, the distance between the crystal faces, and the relative intensity Are shown in Table 1 below.

 2? (?) D 1/1.  2? (?) D 1/1. 9.98 8.85 46.0
10.66 8.29 36.4
13.49 6.56 27.1
14.18 6.24 23.7
15.60 5.68 38.5
15.88 5.58 39.2
16.32 5.43 37.2
16.76 5.29 37.3
17.39 5.60 100.0
18.09 4.90 47.5
19.54 4.54 55.8
19.89 4.46 56.5
20.74 4.28 37.4
22.28 3.99 37.6 23.39 3.80 57.0
24.74 3.60 83.3
25.25 3.52 65.7
27.39 3.25 31.9
29.07 3.06 30.1
29.77 3.00 28.1
29.94 2.98 30.4
30.63 2.92 30.5
31.08 2.88 27.9
32.43 2.76 30.3
33.06 2.71 30.6
34.62 2.59 18.9
42.49 2.13 19.4

Here, 2θ is the diffraction angle, d is the distance, Ⅰ / I ₀ between the crystal plane represents the relative intensity of each peak intensity (1) for the intensity ₍₁₀₎ of the largest peak.

Example  2. (S) -Crystal Bepotastine  Produce

(S) -bipotastine (5.0 g) is dissolved in 30 ml of tetrahydrofuran and made into a homogeneous solution. After stirring at room temperature for 30 hours, the solvent was removed by reduced pressure, and further 25 ml of ethyl acetate was added to the residue, followed by stirring at room temperature for 12 hours.

The solvent was removed by further decompression, 50 ml of acetonitrile was added to the residue, and the mixture was stirred at room temperature for 6 hours to obtain 4.5 g of the title compound as a crystalline form.

Melting point: 160-163 ° C

¹ H NMR (CDCl ₃ ):? 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 (4H), 3.5 (1H), 5.45 (1H), 7.0-7.2 (4H), 7.6-7.8 (1H), 8.5 (1H)

IR (KBr): 3348 cm-, 2931 cm-, 2345 cm-, 1728 cm-, 1590 cm-, 1172 cm-, 1080 cm-.

HPLC (purity): 99.99% or more

* HPLC (optical purity): 99.9% or more

Example  3. (S) -Crystal Bepotastine  Produce

(S) -bipotastine (5.0 g) is added to 60 ml of toluene to make a homogeneous solution under reflux.

After stirring at room temperature for 60 hours, the solvent was removed from the reaction solution under reduced pressure, and 60 ml of ethyl acetate was further added to the residue, followed by stirring at room temperature for 12 hours.

The solvent was removed by further decompression, 100 ml of acetone was added to the residue, and the mixture was stirred at room temperature for 5 hours to obtain 4.95 g of the desired compound as a crystalline form.

Melting point: 160-163 ° C

¹ H NMR (CDCl ₃ ):? 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 (4H), 3.5 (1H), 5.45 (1H), 7.0-7.2 (4H), 7.6-7.8 (1H), 8.5 (1H)

IR (KBr): 3348 cm-, 2931 cm-, 2345 cm-, 1728 cm-, 1590 cm-, 1172 cm-, 1080 cm-.

HPLC (purity): 99.99% or more

HPLC (optical purity): 99.95% or more

Example  4. (S) -Crystal Bepotastine  Produce

(S) -bipotastine (5.0 g) is dissolved in dioxane (100 ml) to obtain a homogeneous solution.

After stirring at room temperature for 32 hours, the solvent was removed from the solution under reduced pressure, and 260 ml of diglyme was added to the residue, followed by stirring at room temperature for 12 hours.

The solvent was removed by further decompression, 100 ml of acetonitrile was added to the residue, and the mixture was stirred at room temperature for 4 hours to obtain 4.4 g of the target compound as a crystal form.

Melting point: 160-163 ° C

¹ H NMR (CDCl ₃ ):? 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 (4H), 3.5 (1H), 5.45 (1H), 7.0-7.2 (4H), 7.6-7.8 (1H), 8.5 (1H)

IR (KBr): 3348 cm-, 2931 cm-, 2345 cm-, 1728 cm-, 1590 cm-, 1172 cm-, 1080 cm-.

HPLC (purity): 99.99% or more

HPLC (optical purity): 99.95% or more

Example  5. (S) -Crystal Bepotastine  Produce

5.0 g of (S) -bipotastine is dissolved in 100 ml of acetone, and 20 ml of water is added to the solution to make a homogeneous solution.

After stirring at room temperature for 48 hours, the solvent was removed from the solution under reduced pressure, and 60 ml of ethanol was further added to the residue, followed by stirring at room temperature for 12 hours.

The solvent was removed by further decompression, and 50 ml of diphenyl ether was added to the residue. The mixture was stirred at room temperature for 5 hours to obtain the desired compound (5.1 g) as a crystalline form.

Melting point: 160-163 ° C

¹ H NMR (CDCl ₃ ):? 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 (4H), 3.5 (1H), 5.45 (1H), 7.0-7.2 (4H), 7.6-7.8 (1H), 8.5 (1H)

IR (KBr): 3348 cm-, 2931 cm-, 2345 cm-, 1728 cm-, 1590 cm-, 1172 cm-, 1080 cm-.

HPLC (purity): 99.99% or more

* HPLC (optical purity): 99.9% or more

Example  6. (S) -Crystal Bepotastine  Produce

(S) -bipotastine (5.0 g) is dissolved in 60 ml of methanol, and 10 ml of water is added to the solution to obtain a homogeneous solution.

After stirring at room temperature for 60 hours, the solvent was removed from the reaction solution under reduced pressure, and 60 ml of methyl ethyl ketone was added to the residue, followed by stirring at room temperature for 12 hours.

The solvent was removed by further decompression, 100 ml of acetonitrile was added to the residue, and the mixture was stirred at room temperature for 8 hours to obtain the desired compound (5.15 g) as a crystalline form.

Melting point: 160-163 ° C

¹ H NMR (CDCl ₃ ):? 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 (4H), 3.5 (1H), 5.45 (1H), 7.0-7.2 (4H), 7.6-7.8 (1H), 8.5 (1H)

IR (KBr): 3348 cm-, 2931 cm-, 2345 cm-, 1728 cm-, 1590 cm-, 1172 cm-, 1080 cm-.

HPLC (purity): 99.99% or more

HPLC (optical purity): 99.5% or more

Example  7. (S) -Crystal Bepotastine  Produce

(S) -bipotastine (5.0 g) is dissolved in 100 ml of dimethylformamide to obtain a homogeneous solution.

After stirring at room temperature for 3 hours, the solvent was removed by reducing the pressure of the reaction solution, and 260 ml of methyl ethyl ketone was added to the residue, followed by stirring at room temperature for 12 hours.

The solvent was distilled off under reduced pressure, and 100 ml of acetonitrile was added to the residue. The mixture was stirred at room temperature for 6 hours to obtain the desired compound (4.4 g) as a crystalline form.

Melting point: 160-163 ° C

¹ H NMR (CDCl ₃ ):? 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 (4H), 3.5 (1H), 5.45 (1H), 7.0-7.2 (4H), 7.6-7.8 (1H), 8.5 (1H)

IR (KBr): 3348 cm-, 2931 cm-, 2345 cm-, 1728 cm-, 1590 cm-, 1172 cm-, 1080 cm-.

HPLC (purity): 99.99% or more

HPLC (optical purity): 99.95% or more

Example  8. (S) -Crystal Bepotastine  Produce

5.0 g of (S) -bipotastine is dissolved in 100 ml of furovanol, dissolved in 20 ml of water, and added to the solution to make a homogeneous solution.

After stirring at room temperature for 33 hours, the solvent was removed by reduced pressure, and 60 ml of dimethoxyethane was added to the residue, followed by stirring at room temperature for 12 hours.

The solvent was removed by further decompression, 50 ml of acetonitrile was added to the residue, and the mixture was stirred at room temperature for 72 hours to obtain 5.0 g of the aimed compound as a crystalline form.

Melting point: 160-163 ° C

¹ H NMR (CDCl ₃ ):? 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 (4H), 3.5 (1H), 5.45 (1H), 7.0-7.2 (4H), 7.6-7.8 (1H), 8.5 (1H)

IR (KBr): 3348 cm-, 2931 cm-, 2345 cm-, 1728 cm-, 1590 cm-, 1172 cm-, 1080 cm-.

HPLC (purity): 99.9% or more

HPLC (optical purity): 99.9% or more

Example  9. (S) -Crystal Bepotastine  Produce

(S) -bipotastine (5.0 g) is dissolved in 60 ml of butanol and added to 10 ml of water to make a homogeneous solution.

After stirring at room temperature for 48 hours, the solvent was removed by reduced pressure, and 60 ml of methyl acetate was added to the residue, followed by stirring at room temperature for 12 hours.

The solvent was removed by reduced pressure, 100 ml of acetonitrile was added to the residue, and the mixture was stirred at room temperature for 8 hours to obtain 4.8 g of the target compound as a crystal form.

Melting point: 160-163 ° C

¹ H NMR (CDCl ₃ ):? 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 (4H), 3.5 (1H), 5.45 (1H), 7.0-7.2 (4H), 7.6-7.8 (1H), 8.5 (1H)

IR (KBr): 3348 cm-, 2931 cm-, 2345 cm-, 1728 cm-, 1590 cm-, 1172 cm-, 1080 cm-.

HPLC (purity): 99.99% or more

HPLC (optical purity): 99.9% or more

Example  10. (R) - (-) - a- (4- Chlorophenyl )-2- Of pyridyl methyl chloride  synthesis

(22.8 mM) of (S) - (+) - (4-chlorophenyl) -2-pyridylmethanol was added to 30 ml of xylene, 7.5 ml (11 mM) of pyridine was added thereto, (25 mM) at 0 < 0 > C. After stirring for 2 hours, the temperature is slowly raised to 20 ° C, stirred for another 2 hours at 30 ° C and then cooled again to 0-5 ° C. 30 ml of distilled water was carefully added to the mixture, and then 35 ml of concentrated ammonia water was slowly added thereto. After confirming that the mixture becomes strong alkali, the layers are separated, and the organic layer is washed with distilled water, saturated saline, and distilled water in 10 ml increments. The solution is dried with anhydrous magnesium sulfate for 10 minutes and filtered. The filtrate was distilled under reduced pressure to remove xylene to obtain 0.5 g (92.3%) of the title compound.

_{^{1 H NMR (CDCl 3):}} δ 5.6 (1H), 7.0-7.2 (2H), 7.2-7.6 (4H), 7.6-7.8 (1H), 8.5 (1H)

This material is used for the next reaction without any post-treatment.

Example  11. (R) - (-) - a- (4- Chlorophenyl )-2- Of pyridyl methyl chloride  synthesis

(22.8 mM) of (S) - (+) - (4-chlorophenyl) -2-pyridylmethanol was added to 50 ml of methylene chloride, 7.5 ml (11 mM) of pyridine was added thereto, 4.4 g (23 mM) of phosphoryl chloride are added at 0 < 0 > C. The mixture is stirred for 3 hours while maintaining the temperature, and then cooled to -30 캜. 2 ml (25 mM) of thionyl chloride is added dropwise to the reaction mixture. After stirring for 2 hours, the temperature is slowly raised to 30 < 0 > C and stirred at this temperature for 3 hours. After confirming that the reaction is complete, cool to 0-5 ° C. 60 ml of distilled water was slowly added dropwise to the mixture, and then 70 ml of concentrated ammonia water was added dropwise. After confirming that the solution becomes alkaline, the layers are separated, and the organic layer is washed with 20 ml of distilled water, saturated saline solution and distilled water in order. The solution is dried with anhydrous magnesium sulfate for 10 minutes and filtered. The filtrate was distilled off under reduced pressure, and methylene chloride was removed to obtain 0.51 g (93.9%) of the title compound.

_{^{1 H NMR (CDCl 3):}} δ 5.6 (1H), 7.0-7.2 (2H) 7.2-7.6 (4H), 7.6-7.8 (1H), 8.5 (1H)

Example 12. Synthesis of (S) -4- [4- [(4 -chlorophenyl ) - (2 -pyridyl ) methoxy ] piperidino ] butanoic acid ethyl ester

(0.1 mol) of ethyl 4- (4-hydroxypiperidinyl) -butanoate and 23.8 g (0.1 mol) of (R) - (-) - 4-chlorophenyl- To 200 ml of methyl ethyl ketone, the mixture is reacted under reflux for 4 hours. The solution is cooled and the precipitated crystals are filtered off. The solution was concentrated under reduced pressure to obtain 36.2 g of (S) - (+) - 4- [4 - [(4-chlorophenyl) - (2-pyridyl) methoxy] piperidino] butanoic acid ethyl ester as an oil ≪ / RTI > (Yield: 90%, optical purity: 99.9%, e.e.).

¹ H NMR (CDCl ₃ ): δ 1.0-1.3 (3H), 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 ), 7.0-7.2 (2H), 7.2-7.6 (4H), 7.6-7.8 (1H), 8.5 (1H).

Example 13. Synthesis of (S) -4- [4- [(4 -chlorophenyl ) - (2 -pyridyl ) methoxy ] piperidino ] butanoic acid ethyl ester

(0.1 mol) of ethyl 4- (4-hydroxypiperidinyl) -butanoate and 23.8 g (0.1 mol) of (R) - (-) - [4- chlorophenyl- Was added to 200 ml of methyl isobutyl ketone and the mixture was reacted under reflux for 4 hours. The solution is cooled and the precipitated crystals are filtered off. The solution was concentrated under reduced pressure to obtain 36.2 g of (S) -4- [4 - [(4-chlorophenyl) - (2-pyridyl) methoxy] piperidino] butanoic acid ethyl ester as an oil. (Yield: 90%, optical purity: 99.9%, e.e.).

¹ H NMR (CDCl ₃ ): δ 1.0-1.3 (3H), 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 ), 7.0-7.2 (2H), 7.2-7.6 (4H), 7.6-7.8 (1H), 8.5 (1H).

Example 14 Synthesis of (S) -4- [4- [(4 -chlorophenyl ) - (2 -pyridyl ) methoxy ] piperidino ] butanoic acid ethyl ester

(0.1 mol) of ethyl 4- (4-hydroxypiperidinyl) -butanoate and 28.3 g (0.1 mol) of (R) - (-) - 4- chlorophenyl- To 200 ml of acetone, the mixture was reacted under reflux for 4 hours. The solution is cooled and the precipitated crystals are filtered off. The solution was concentrated under reduced pressure to obtain 36.2 g of (S) -4- [4 - [(4-chlorophenyl) - (2-pyridyl) methoxy] piperidino] butanoic acid ethyl ester as an oil. (Yield: 90%, optical purity: 99.9%, e.e.).

¹ H NMR (CDCl ₃ ): δ 1.0-1.3 (3H), 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 ), 7.0-7.2 (2H), 7.2-7.6 (4H), 7.6-7.8 (1H), 8.5 (1H).

Example 15. Synthesis of (S) -4- [4- [(4 -chlorophenyl ) - (2 -pyridyl ) methoxy ] piperidino ] -butyronitrile

23.8 g (0.1 mole) of S - (+) - 4-chlorophenyl-2-pyridyl methyl chloride was dissolved in 200 ml of anhydrous acetonitrile, and 2.53 g (0.11 mole) of sodium was added thereto. 16.7 g (0.1 mol) of ethyl 4- (4-hydroxypiperidinyl) -butyronitrile was added to dissolve and the mixture was reacted under reflux for 4 hours. The solution is cooled and the precipitated crystals are filtered off. The solution was concentrated under reduced pressure to obtain 35.9 g of (S) -4- [4- [(4-chlorophenyl) - (2-pyridyl) methoxy] piperidino] butyronitrile as an oil. (Yield: 97%, optical purity: 99.9%, e.e.).

¹ H NMR (CDCl ₃ ):? 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 (4H), 3.5 (1H), 5.45 (1H), 7.0-7.2 (4H), 7.6-7.8 (1H), 8.5 (1H).

Example 16. Synthesis of (S) -4- [4- [(4 -chlorophenyl ) - (2 -pyridyl ) methoxy ] piperidino ] -butyronitrile

28.3 g (0.1 mol) of S - (+) - 4-chlorophenyl-2-pyridyl-methyl bromide are dissolved in 200 ml of anhydrous tetrahydrofuran, to which 2.53 g (0.11 mol) of sodium is added. After blocking the water, 16.7 g (0.1 mol) of 4- (4-hydroxypiperidinyl) -butyronitrile was added to dissolve the solution, and the solution was reacted under reflux for 4 hours. The solution is cooled and the precipitated crystals are filtered off. The solution was concentrated under reduced pressure to obtain 35.9 g of (S) -4- [4- [(4-chlorophenyl) - (2-pyridyl) methoxy] piperidino] butyronitrile as an oil. (Yield: 97%, optical purity: 99.9%, e.e.).

_{^{1 H NMR (CDCl 3):}} δ 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 (4H), 3.5 (1H), 5.45 (1H), 7.0-7.2 (2), 7.2-7.6 (4H), 7.6-7.8 (1H), 8.5 (1H).

Example 17. Synthesis of (S) -4- [4- [(4 -chlorophenyl ) - (2 -pyridyl ) methoxy ] piperidino ] butanoic acid

36.2 g (0.1 mol) of (S) -4- [4 - [(4-chlorophenyl) - (2-pyridyl) methoxy] piperidino] butanoic acid ethyl ester obtained in Example 12 was dissolved in 220 ml of ethanol After dissolving, 34.7 ml of 5 N sodium hydroxide solution was left for 12 hours, and then an equivalent amount of 5 N hydrochloric acid was added to neutralize the solution. The precipitated sodium chloride was removed by filtration, and the reaction mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (170 ml), dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated to obtain the desired compound (33.6 g).

[a] _D25 + 3.4 [deg.] (C = 5, MeOH).

¹ H NMR (CDCl ₃ ):? 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 (4H), 3.5 (1H), 5.45 (1H), 7.0-7.2 (4H), 7.6-7.8 (1H), 8.5 (1H).

Example 18. Synthesis of (S) -4- [4 - [(4 -chlorophenyl ) - (2 -pyridyl ) methoxy ] piperidino ] butanoic acid

37 g (0.1 mole) of the (S) -4- [4 - [(4-chlorophenyl) - (2-pyridyl) methoxy] piperidino] butyronitrile obtained in Example 16 was dissolved in 5 N sodium hydroxide solution And the mixture was refluxed for 12 hours, followed by neutralization by addition of an equivalent amount of 5 N hydrochloric acid. The target compound (38.7 g) was obtained as an amorphous amber syrup on the basis of the procedure of Example 17. The XRD spectrum and the IR spectrum of the obtained amorphous bepotastine are shown in Fig. 3 and Fig. 4, respectively.

[a] _D25 + 3.4 [deg.] (C = 5, MeOH).

¹ H NMR (CDCl ₃ ):? 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 (4H), 3.5 (1H), 5.45 (1H), 7.0-7.2 (4H), 7.6-7.8 (1H), 8.5 (1H).

Example  19. Etch  4- [4- Hydroxypiperidinyl ] Butyrate  synthesis

18 g of 4-hydroxypiperidine, 450 ml of methyl isobutyl ketone, 30 ml of ethyl 4-bromobutyrate, 49 g of potassium carbonate and a catalytic amount of potassium iodide were added and heated. Reflux for 24 hours, then cool to room temperature and add 100 ml of cold water. The mixture was extracted with 100 ml of ethyl acetate, layered and dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain 28.5 g (74.5%) of the aimed compound as an oil.

¹ H NMR (CDCl ₃ ):? 1.2 (3H), 1.8-2.2 (4H), 2.3-2.6 (6H), 2.4-2.8 (4H), 3.4 (1H), 4.0 (2H).

Example  20. 4- [4- Hydroxypiperidinyl ] Butyronitrile  synthesis

18 g of 4-hydroxypiperidine, 450 ml of methyl isobutyl ketone, 20 ml of 4-bromobutyronitrile, 49 g of potassium carbonate and a catalytic amount of potassium iodide were added and heated. Reflux for 24 hours, then cool to room temperature and add 100 ml of cold water. The mixture was extracted with 100 ml of ethyl acetate, layered, dried over anhydrous magnesium sulfate, and then the solvent was removed under reduced pressure to obtain 24 g (80%) of the aimed compound as an oil.

_{^{1 H NMR (CDCl 3):}} δ 1.8-2.2 (4H), 2.3-2.6 (6H), 2.4-2.8 (4H), 3.4 (1H).

Example  21. (S) - Bepotastine  benzene Sulfonate  Produce

(S) -bipotastine (5.0 g) is dissolved in 260 ml of ethyl acetate, and 2 g of benzenesulfonic acid monohydrate is added to make a homogeneous solution. The solvent was removed from the solution under reduced pressure, and 260 ml of ethyl acetate was added to the residue, followed by stirring for 12 hours. The solvent was removed again by decantation, 100 ml of acetonitrile was added to the residue, and the mixture was stirred at room temperature for 3 days to obtain the title compound (3 g).

Melting point: 159-163 ° C

¹ H NMR (CDCl ₃ ):? 1.8-2.2 (6H), 2.3-2.6 (4H), 2.4-2.8 (4H), 3.5 (1H), 5.45 (1H), 7.0-7.2 (9H), 7.6-7.8 (1H), 8.5 (1H)

Test Example  1. Hygroscopicity test

The amorphous beportastine obtained in Example 18, the bevetastine benzenesulfonate obtained in Example 21 by the known method and the crystalline beatifastine obtained in Example 1 were subjected to a hygroscopicity test under the following conditions .

(1) 25 ° C, 75% relative humidity

(2) 40 < 0 > C, 75% relative humidity

(3) Moisture content was measured at 3 days, 7 days, 15 days, 21 days, and 28 days after being allowed to stand for 15 days under conditions of 40 DEG C and 90% relative humidity. Respectively.

Hygroscopicity comparison division Temperature, relative humidity Water content (%) Early 3 days 7 days 15th 21st 28th Bepotastine
Amorphous 25, 75% 0.5 5.0 7.0 10.0 15.0 20.0 40, 75% 0.5 6.0 8.0 12.0 18.0 25.0 40, 90% 0.5 7.0 9.0 13.0 19.0 26.0 benzene
Sulfonate 25, 75% 0.4 0.6 0.6 0.7 0.6 0.6 40, 75% 0.4 0.7 0.8 0.8 0.9 0.9 40, 90% 0.4 2.4 2.4 2.4 2.5 2.5 Bepotastine
Crystal form 25, 75% 0.01 0.01 0.01 0.01 0.01 0.02 40, 75% 0.01 0.01 0.01 0.01 0.01 0.02 40, 90% 0.01 0.01 0.01 0.01 0.01 0.02

As can be seen from the above Table 2, in the case of crystalline beatifastine, there was little increase in moisture content, but there was a slight increase at 28 days. However, at 40 ° C and 90% relative humidity, , The bepotastine benzenesulfonate showed a moisture content increase of at most 2.5%, whereas the beportastine according to the present invention showed a moisture content increase of 0.02%. Thus, it can be confirmed that the product of the present invention is non-hygroscopic.

As can be seen from the above Table 2, the crystalline beatifastine of the present invention is extremely low in hygroscopicity as compared with the known amorphous bevetastatin and beportastine benzenesulfonate salts, It has been confirmed that the material is a stable material having little hardness.

Formulation Example  One. Bepotastine  Manufacture of tablets

10.0 mg of crystalline beatifastine

Microcrystalline cellulose 12.0 mg

Lactose 60.0 mg

Polyethylene glycol 10.0 mg

Colloidal silicon dioxide 1.0 mg

Magnesium stearate 1.50 mg

Opadry Y 1 7000 3.0 mg

Gross weight 97.5 mg

After mixing the above components, tablets were prepared by dry or wet pressing according to a conventional tablet preparation method.

Formulation Example  2. Bepotastine  Manufacture of tablets

10.0 mg of crystalline beatifastine

Microcrystalline cellulose 40.0 mg

D-mannitol 20.0 mg

Hydroxypropylcellulose 25 mg

15 mg of hydroxypropylcellulose phthalate

Talc 2.0 mg

Magnesium stearate 1.50 mg

Opadry Y 1 7000 3.0 mg

Gross weight 116.5 mg

The above components were mixed and filled in gelatin capsules according to a conventional capsule preparation method to prepare tablets.

Formulation Example  3. Bepotastine  Manufacture of tablets

10.0 mg of crystalline beatifastine

Ethyl oleate 12.0 mg

Lactose 60.0 mg

Polyethylene glycol 10.0 mg

Colloidal silicon dioxide 1.0 mg

Magnesium stearate 1.50 mg

Opadry Y 1 7000 3.0 mg

Gross weight 96.5 mg

After mixing the above components, tablets were prepared by dry or wet pressing according to a conventional tablet preparation method.

Formulation Example  4. Bepotastine  Manufacture of tablets

10.0 mg of crystalline beatifastine

Microcrystalline cellulose 40.0 mg

D-mannitol 20.0 mg

Propylene glycol 25 mg

15 mg of hydroxypropylcellulose phthalate

Talc 2.0 mg

Magnesium stearate 1.50 mg

Opadry Y 1 7000 3.0 mg

Gross weight 116.5 mg

The above components were mixed and filled in gelatin capsules according to the conventional preparation method of capsules to prepare capsules.

Claims (3)

(I) having a diffraction angle (2?), A distance (d) between crystal faces and a relative intensity (I / I ₀ ) in the X-ray powder diffraction spectroscopy and having a water content of 0.01 to 0.02% (S) -4- [4 - [(4-chlorophenyl) - (2-pyridyl) methoxy] piperidin-1-yl] butanoic acid (bepotastine).

(doing)

Here, 2? Represents the diffraction angle, d represents the distance between the crystal faces, and I / I ₀ represents the relative intensity of intensity (I / I ₀ ) of each peak to intensity (I ₀ ) of the largest peak. Moisture content was measured after leaving for 15 days at 25 ~ 40 ℃, 75 ~ 90% relative humidity. (S) -4- [4- [4-chlorophenyl) - (2-pyridyl) methoxy] piperidin- 1-yl] butanoic acid (bepotastine) of claim 1 and at least one excipient Or an anti-allergic agent. The oral preparation according to claim 2, wherein the pharmaceutical composition is selected from tablets, capsules and powders.

Images